Cargando…

Beyond Kras: MYC Rules in Pancreatic Cancer

Detalles Bibliográficos
Autor principal:	Korc, Murray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085492/ https://www.ncbi.nlm.nih.gov/pubmed/30105283 http://dx.doi.org/10.1016/j.jcmgh.2018.04.009

Ejemplares similares

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Sugar-Coated Proteins Pave the Way to Improving Pancreatic Cancer Diagnosis
por: Korc, Murray
Publicado: (2016)

Acute Pancreatitis Accelerates Initiation and Progression to Pancreatic Cancer in Mice Expressing Oncogenic Kras in the Nestin Cell Lineage
por: Carrière, Catherine, et al.
Publicado: (2011)

A Kras(G12D)-Driven Genetic Mouse Model of Pancreatic Cancer Requires Glypican-1 for Efficient Proliferation and Angiogenesis
por: Whipple, Chery A., et al.
Publicado: (2011)

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
por: Entrialgo-Cadierno, Rodrigo, et al.
Publicado: (2023)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
por: Grinshpun, Albert, et al.
Publicado: (2019)

Heparin Prowess: Favorable Vascular–Immune Reprogramming in Pancreatic Cancer
por: Korc, Murray
Publicado: (2023)

Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
por: Entrialgo‑Cadierno, Rodrigo, et al.
Publicado: (2023)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

Pathways for aberrant angiogenesis in pancreatic cancer
por: Korc, M
Publicado: (2003)

KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
por: Ischenko, Irene, et al.
Publicado: (2017)

Ten simple rules for developing good reading habits during graduate school and beyond
por: Méndez, Marcos
Publicado: (2018)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Personalized treatment for advanced colorectal cancer: KRAS and beyond
por: Patel, Gargi Surendra, et al.
Publicado: (2013)

Concomitant Targeting of EGF Receptor, TGF-beta and Src Points to a Novel Therapeutic Approach in Pancreatic Cancer
por: Deharvengt, Sophie, et al.
Publicado: (2012)

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
por: Diersch, Sandra, et al.
Publicado: (2015)

MYC and integrins interplay in colorectal cancer
por: Boudjadi, Salah, et al.
Publicado: (2016)

Metabolic vulnerabilities of MYC-induced cancer
por: Gouw, Arvin M., et al.
Publicado: (2016)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance
por: Martínez-Galán, Joaquina, et al.
Publicado: (2021)

Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis
por: Yoshida, Mitsuyo, et al.
Publicado: (2016)

Critical role of NF-κB in pancreatic cancer
por: Prabhu, Lakshmi, et al.
Publicado: (2014)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Myc beyond Cancer: Regulation of Mammalian Tissue Regeneration
por: Illi, Barbara, et al.
Publicado: (2023)

Understanding KRAS for better targeting
por: Patel, Ronak, et al.
Publicado: (2023)

Zebrafish model of KRAS-initiated pancreatic cancer
por: Park, Joon Tae, et al.
Publicado: (2018)

KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion
por: Sabe, Hisataka
Publicado: (2023)

MYC in Regulating Immunity: Metabolism and Beyond
por: Gnanaprakasam, J.N. Rashida, et al.
Publicado: (2017)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
por: Liu, Fang, et al.
Publicado: (2014)

Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
por: Craven, Kelly E., et al.
Publicado: (2015)

Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis
por: Best, Sarah A., et al.
Publicado: (2020)

Epithelial Splicing Regulatory Protein 1 is a Favorable Prognostic Factor in Pancreatic Cancer that Attenuates Pancreatic Metastases
por: Ueda, Junji, et al.
Publicado: (2013)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation
por: De Falco, Giulia, et al.
Publicado: (2015)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy
por: Pereira, Cynthia Brito Lins, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s8sbi5t00iv9jsd7b1c5pjtruk